Michael Vi/iStock Editorial via Getty Images RNA medicine developer Ascidian Therapeutics announced a research and licensing agreement with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) on Tuesday to develop treatments targeted at neurological diseases. As part of the deal, Roche ( OTCQX:RHHBF ) will receive exclusive rights to Ascidian's RNA exon editing technology to target specific undisclosed neurological targets. The duo will jointly conduct certain preclinical activities before the Swiss pharma giant takes over the clinical development, manufacturing, and commercialization of drugs resulting from the collaboration.
In exchange, Boston-based Ascidian will receive $42M upfront, up to $1.8B in research, clinical, and commercial milestone payments, and royalties on global commercial sales. The agreement will not preclude Ascidian from developing programs against other neurological targets in partnership with other parties or using its internal resources.
More on Roche Holding Roche Is Joining The Obesity Party But Questions Remain Emerging Leaders: Roche And Viking Therapeutics In The Obesity Treatment Race Roche: Targeting Mega-Money Obesity Markets After Sharing Stunning Weight Loss Data CDC worried about 'dual mutant' flu strains resistant to antiviral meds Sarepta gains after Pfizer’s late-stage setback for Duchenne therapy.
